Investigational drug · Phase 3
HLX04-O
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Age Related Macular Degeneration.
Phase 3Last checked: Nov 20, 2026Latest source record: Jan 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "HLX04-O"
First trial start
2021
Jul 1, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX04-O", any sponsor or status.
Conditions studied
As listed on its trial records.
- Age Related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX04-O" as an intervention, largest first.
- A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDPivotal-lookingCompleted
Shanghai Henlius BiotechIndustry
NCT04740671 · 410 participants · Start Jul 1, 2021 · Primary completion Dec 31, 2024
Drug: HLX04-O; ranibizumab · For: Age Related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Fullerton, California · 126 sites in all
- Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDPivotal-lookingCompleted
Shanghai Henlius BiotechIndustry
NCT05003245 · 407 participants · Start Nov 1, 2021 · Primary completion May 7, 2024
Drug: HLX04-O,recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection; Lucentis · For: Age Related Macular Degeneration
Sites: Bengbu, China; Hefei, China; Beijing, China · 41 sites in all
Shanghai Henlius BiotechIndustry
NCT04993352 · 20 participants · Start Jul 15, 2021 · Primary completion Jul 7, 2022
Drug: recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection · For: Age Related Macular Degeneration
Sites: Xuzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of intravitreal HLX04-O, an anti-VEGF monoclonal antibody, for the treatment of wet age-related macular degeneration.
Zhang Z, Wu Y, Lyu YL, et al. · Int J Ophthalmol 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.